Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
clinical trials
life sciences
national blog main
amgen
eli lilly
fda
indiana blog main
indiana top stories
migraine
new york blog main
raleigh-durham blog main
raleigh-durham top stories
teva pharmaceutical
boston blog main
calcitonin gene-related peptide
chronic migraine
migraine research foundation
national
national top stories
new york top stories
san francisco blog main
san francisco top stories
allergan
biohaven
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
episodic migraine
eptinezumab
erenumab
fremanezumab
galcanezumab
impel neuropharma
indiana
lasmiditan
medical device
What
migraine
6
×
drug
fda
new
approval
class
won
medicines
approved
companies
decades
developed
eli
lilly
nod
pain
starts
activity
acute
addresses
adults
allergan
amgen
announced
arguments
big
biotech
candidates
causes
commercialized
competitors
condition
days
decision
dog
drugs
firm
friday
gets
giant
Language
unset
Current search:
migraine
×
biotech
×
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines